Conference abstract · 20 Feb 2017
Conference abstractPublished 2017
Vaccines for human viral diseases as well as for oncogenic non viral antigens
Beaumont Bonelli for Cancer Research, Naples, Italy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The Variola major, the virus that causes the smallpox, lethal virus in the 30% of the cases, was eraticated in 1979 in the human species, thanks to a capillary vaccination on global scale. Recently the World Health Organization declared that India and Southeast Asia are polio-free, really a great achievement since the vaccine for polio, an infectious desease that can cause paralisis, was certificated safe and useful only 60 years ago. Last year over 800 million doses of combination vaccines are going to be used to vaccinate Chinese children whereas more than 20 million children worldwide do not receive one or more important vaccinations that would protect them from at least one preventable disease. Research is badly needed to develop strategies to communicate the importance of vaccinations to uncertain parents. The 2008 San Diego measles outbreack costed over 10.000 dollars for each infection in comparisons to the total cost to contain the outbreack (approximately 124.000 dollars). Even if there are rare cases of vaccine damage, the research to facilitate vaccination must be done to prevent diseases. The vaccine for HBV virus, responsible for epatitis B infection, is able to prevent 50% of all liver cancers. Human Papilloma Viruses (HPV) have been correlated with the cervical cancer (genotypes 16 and 18 particularly oncogenic in humans): the USA Food and Drug Administration in 2006 released the first vaccine against HPV. Long years of research where required for busting the new system to fight cancer. Research is going to obtain the complete sequence by proteomics approaches, in order to achieve adequate antigen preparations that might be used to generate assays for a specific anticancer vaccine. Finally, the ability of the immune system to recognize a tumor-associated antigen, thus enabling development of a vaccine approach for therapeutic application, represents a main target of this field of research.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 3 Jun 2019
The future of nucleic acid vaccines and non-viral delivery systems
Conference abstract · 3 Jun 2019
The human viral challenge model-accelerating vaccine development
Conference abstract · 6 Dec 2018
Recombinant approach to develop ScFv antibodies and vaccines against viral diseases as Ebola, Flu (AH1N1) and Cancer (Polyomavirus)Antibiotic use in relation with long term morbidities
Conference abstract · 6 Dec 2018
Recombinant approach to develope ScFv antibodies and vaccines against viral diseases as ebola, flu (AH1N1) and cancer (polyomavirus)
More from this journal
The newest in Journal of Immunological Techniques & Infectious Diseases.
Research article · 14 Feb 2025
A Pattern of Cytokine Response in Suspected HIV-Negative Tuberculous Meningitis Patients, a Study from Tertiary Neurocenter in India
Review article · 17 Jan 2025
Vitiligo is a Breakdown of the Melanocyte-Immune Tolerance
Short communication · 25 Sep 2024
Pediatric Infections: A Comprehensive Overview of Common Illnesses and Management
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Immunological Techniques & Infectious Diseases
- SubjectImmunology & Microbiology
- SubjectInfectious Diseases
- BylineArticles whose byline prints “Giulio Tarro”

